newsfilter
← Latest News
GlobeNewswire·

Decibel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

- Key anticipated catalysts in 2022 include submission of IND and/or CTA for DB-OTO and results from interim analysis from Phase 1b trial of DB-020 for cisplatin-induced hearing loss - - Research term extended under strategic collaboration with Regene